RxDoctor Payments Data

Alvaro Gomez, MD

Interventional Cardiology · Miami, FLNPI 1710994736

Payments from drug & device makers

$70,664in general payments, 2019–2025

Across 311 payments — averaging $227.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Circulation Inc$45K
  • Siemens Medical Solutions USA, Inc.$13K
  • Abbott$2K
  • Boston Scientific$2K
  • Abiomed$2K
  • Medtronic$1K
  • plus $6K from 35 others

What the payments were for

  • Consulting fees$11,00016%
  • Speaking & faculty fees$35,36550%
  • Travel & lodging$11,07716%
  • Food & beverage$13,10419%
  • Education$1170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$70,664 in reported general payments places this provider in the 80th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$150,308
Medicare patients
630
Services billed
1,771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban361$417,260
EntrestoSacubitril/Valsartan223$266,049
FarxigaDapagliflozin Propanediol124$130,825
Repatha SureclickEvolocumab83$94,094
VascepaIcosapent Ethyl124$88,543
XareltoRivaroxaban58$72,493
MultaqDronedarone Hcl20$33,723
BrilintaTicagrelor24$30,299
JardianceEmpagliflozin26$30,146
Praluent PenAlirocumab20$26,435
Metoprolol Succinate543$6,351
Atorvastatin Calcium677$6,231
Ezetimibe278$5,071
Rosuvastatin Calcium365$4,454
Ranolazine ErRanolazine20$3,328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$305$417,260361 claims
NovartisEntresto$203$266,049223 claims
AstraZenecaFarxiga, Brilinta$114$161,124148 claims
Johnson & JohnsonXarelto$455$72,49358 claims
Sanofi-aventis U.S. LLCMultaq$160$33,72320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →